Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.71 |
| ▸ | SCARB1 | Q8WTV0 | 11/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900750 | 0.89 | MAPK14 (0.69) | MAPK14SCARB1KDM4EALDH1A1MAPT | |
| SCHEMBL1905020 | 0.89 | MAPK14 (0.67) | MAPK14SCARB1KDM4EALDH1A1MAPT | |
| SCHEMBL12669939 | 0.85 | MAPK14 (0.84) | MAPK14SCARB1 | |
| SCHEMBL1600378 | 0.84 | SCARB1 (0.78) | MAPK14SCARB1 | |
| SCHEMBL1600560 | 0.83 | MAPK14 (1.00) | MAPK14SCARB1 | |
| SCHEMBL1902515 | 0.83 | MAPK14 (0.61) | MAPK14SCARB1KDM4EALDH1A1MAPT | |
| SCHEMBL4949131 | 0.83 | MAPK14 (0.61) | MAPK14SCARB1KDM4EALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1899167 | 0.82 | MAPK14 (0.98) | MAPK14SCARB1 | |
| SCHEMBL1600116 | 0.80 | MAPK14 (0.70) | MAPK14SCARB1KDM4EALDH1A1MAPT | |
| SCHEMBL5312935 | 0.77 | MAPK14 (0.57) | MAPK14SCARB1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011063076-A1 | METHODS OF TREATING HEPATITIS C VIRUS WITH OXOACETAMIDE COMPOUNDS | ITHERX PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063076-A1 | METHODS OF TREATING HEPATITIS C VIRUS WITH OXOACETAMIDE COMPOUNDS | ITHERX PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20110117055-A1 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | BRS - TUSTIN SAFEGUARD ASSOCIATES II, LLC | 2011-05-19 | — | — | US | disclosed |
| US-20110117055-A1 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | BRS - TUSTIN SAFEGUARD ASSOCIATES II, LLC | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117055-A1 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | OAT, HAVCR2, OTC | MAPK14 3352/4885SCARB1 922/4885KDM4E 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.